Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells

BACKGROUND: Sorafenib resistance poses therapeutic challenges in HCC treatment, in which cancer stem cells (CSCs) plays a crucial role. CRISPR/Cas9 can be utilized as a potential technique to overcome the drug resistance. However, a safe, efficient and target specific delivery of this platform remai...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Cong, Jaffar Ali, Doulathunnisa, Qi, Yuhua, Li, Yumin, Sun, Beicheng, Liu, Rui, Sun, Bo, Xiao, Zhongdang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193671/
https://www.ncbi.nlm.nih.gov/pubmed/37202772
http://dx.doi.org/10.1186/s12951-023-01902-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193671/
https://www.ncbi.nlm.nih.gov/pubmed/37202772
http://dx.doi.org/10.1186/s12951-023-01902-6

Ejemplares similares